market opportunity

• The market for ophthalmics (eye care pharmaceuticals and over-the-counter eye care products) is approximately $11 billion, growing at a rate of 13 percent.⁽¹⁾
• Allergan’s market share in ophthalmics is 16 percent.⁽¹⁾
• For the sixth consecutive year, Allergan was the fastest-growing global eye care company (excluding retinal therapeutics, where Allergan’s R&D candidates have not yet been commercialized).⁽¹⁾

Built upon a nearly 60-year heritage with expertise in discovering and developing therapeutic agents to help protect and preserve vision, Allergan is a global leader in eye care and the treatment of eye conditions including glaucoma, dry eye and external eye diseases. A few of our flagship products include:

dry eye

OPTIVE™ Lubricant Eye Drops

OPTIVE™ is a next-generation artificial tear with an advanced dual-action formula that provides long-lasting relief from dry eye symptoms. In addition to the United States, OPTIVE™ has recently launched with great success in Italy, Germany, Australia, India, Mexico, Colombia and Brazil.

REFRESH^® Brand Products

The number-one selling brand of artificial tear products worldwide⁽¹⁾, the REFRESH^® line offers a variety of products to relieve dry eye symptoms.

RESTASIS^® (Cyclosporine Ophthalmic Emulsion) 0.05%

RESTASIS^® is the first — and currently only — prescription eye drop approved by the U.S. Food and Drug Administration (FDA) to increase tear production in cases where it may be reduced by inflammation due to chronic dry eye. RESTASIS^® is also available in several other countries, some of which include South Korea, Turkey and Mexico.

glaucoma

ALPHAGAN^® P (Brimonidine Tartrate Ophthalmic Solution) 0.1%

ALPHAGAN^® P 0.1% is indicated for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

COMBIGAN™ (Brimonidine Tartrate/Timolol Maleate Ophthalmic Solution) 0.2%/0.5%

In October 2007, COMBIGAN™ received FDA approval for the reduction of intraocular pressure (IOP) in patients with chronic open-angle glaucoma or ocular hypertension who require additional IOP lowering. Allergan’s launch of COMBIGAN™ in the United States follows approval of COMBIGAN™ in Canada, many member states of the European Union, Australia, Brazil, Mexico, Argentina and South Korea.

GANFORT™ (Bimatoprost/Timolol Ophthalmic Solution)

GANFORT™ is a LUMIGAN^® and timolol fixed-combination product approved by the European Commission and indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to topical beta-blockers or prostaglandin analogues.

LUMIGAN^® (Bimatoprost Ophthalmic Solution) 0.03%

LUMIGAN^® is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

external diseases

ACULAR LS^® (Ketorolac Tromethamine Ophthalmic Solution) 0.4%

ACULAR LS^® is the number-one prescribed non-steroidal anti-inflammatory by U.S. ophthalmologists,⁽²⁾ and is indicated to reduce pain, burning and stinging following corneal refractive surgery.

ZYMAR^® (Gatifloxacin Ophthalmic Solution) 0.3%

ZYMAR^® is the first FDA-approved fourth-generation topical fluoroquinolone indicated for the treatment of bacterial conjunctivitis (commonly referred to as “pink eye”).

PRED FORTE^® (Prednisolone Acetate) 1%

PRED FORTE^® is a topical anti-inflammatory agent for ophthalmic uses.